Rheumatoid Arthritis
Dr. John Cush RheumNow
1 week 3 days ago
Risk of Parkinsons? RA patients have 28% lower Parkinson's risk vs general population (HR 0.72); axSpA had HIGHER risk (HR 1.29). Non-TNF biologics in RA reduced PD risk further (HR 0.74). No effect seen in PsA/axSpA. #EULAR2026 Abstr #POS1116 https://t.co/1vZoZGEu5Z
Mrinalini Dey DrMiniDey
1 week 3 days ago
Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis.
@ElenaNikiUK
@RheumNow #EULAR2026 https://t.co/UmB63QBl7N
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 3 days ago
#EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk:
-VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile)
-No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD
Janet Pope Janetbirdope
1 week 3 days ago
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://twitter.com/eular_ard/status/2062509665024344391
Antoni Chan MD (Prof) synovialjoints
1 week 3 days ago
Abstr LB0003
Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered.
RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia
sheila RHEUMarampa
1 week 3 days ago
Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD.
Curious about long term results and potential position in tx strategies
LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO
Jiha Lee JihaRheum
1 week 3 days ago
CAR-T without the CAR-T risks?
AB-101, an off-the-shelf NK cell therapy + RTX, delivered in refractory RA, Sjögren, and SSc (n=31): RA ACR50 71%, SSc mRSS -9.5, SjD ClinESS DAI -8.6 at 6 mo. Outpatient delivery without CAR-T associated AEs? @RheumNow #EULAR2026 LB0003 https://t.co/xi6ZdLwHcN
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 3 days ago
#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC
sheila RHEUMarampa
1 week 3 days ago
Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials.
Identifying high-risk pts and individualizing tx is paramount.
LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq
Antoni Chan MD (Prof) synovialjoints
1 week 3 days ago
Abstr LB0009
Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up.
VTE: HR 1.61 (95% CI 0.97–2.66)
non-inferiority not demonstrated
MACE: HR 1.06 no cardiovascular excess
Serious infections: HR 1.32 (p<0.05)
@RheumNow https://t.co/NSNRJi9B4r
Antoni Chan MD (Prof) synovialjoints
1 week 3 days ago
Abstr LB0009
Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years.
Safety endpoints
VTE HR 1.61 non inferiority not met
Serious infections HR 1.32 (p<0.05)
MACE HR 1.06 reassuring
@RheumNow #EULAR2026 https://t.co/nR6TMowlYS
CD19-directed CAR T-cell therapy has rapidly moved into autoimmune disease, driven in large part by striking reports in SLE, where sustained drug-free remission has raised the possibility of a true immune reset. In RA, where multiple effective therapeutic classes already exist, the relevance of such deep immune interventions remains uncertain.
Jiha Lee JihaRheum
1 week 3 days ago
BARI vs TNFi in VTE-enriched #RA pts (RA-BRIDGE + RA-BRANCH, n=3,640, ~3.7 yrs follow-up): VTE non-inferiority not met (HR 1.61, CI 0.97–2.66).
But absolute rates low (2.5% vs 1.7%) and MACE was similar (HR 1.06). Serious infections ↑ with BARI. @RheumNow #EULAR2026 LB0009
